Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Fineline Cube Apr 30, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Drug

Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil

Fineline Cube Jan 18, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...

Company Drug

Regenxbio’s One-Time Gene Therapy for Wet AMD Shows Promise in Phase II Study

Fineline Cube Jan 17, 2024

Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study...

Company Drug

Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 17, 2024

Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US...

Policy / Regulatory

China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes

Fineline Cube Jan 17, 2024

The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC

Fineline Cube Jan 17, 2024

The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...

Company Drug

Changchun High & New Technology Industries to Launch GenSci125 Phase I Trial in US

Fineline Cube Jan 17, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading Chinese pharmaceutical company,...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Approval for Phase II Cervical Cancer Study

Fineline Cube Jan 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Drug

Roche’s Tecentriq SC Receives European Nod as First Subcutaneous PD-(L)1 Therapy

Fineline Cube Jan 17, 2024

Halozyme Therapeutics (NASDAQ: HALO) has announced that the European Commission (EC) has granted marketing authorization...

Company Drug

Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China

Fineline Cube Jan 17, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of...

Company Deals

Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals

Fineline Cube Jan 17, 2024

Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans...

Company Drug

Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China

Fineline Cube Jan 17, 2024

Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has...

Company Deals

China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers

Fineline Cube Jan 17, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi...

Company Deals

Wuhan EasyDiagnosis Biomedicine Partners with Ailex Technology Group for Global Glycated Hemoglobin Testing Market

Fineline Cube Jan 17, 2024

Wuhan EasyDiagnosis Biomedicine Co., Ltd (SHE: 002932), a Chinese biomedicine company, has announced a strategic...

Company Drug

RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China

Fineline Cube Jan 17, 2024

RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...

Company Legal / IP

WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent

Fineline Cube Jan 17, 2024

WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...

Company Drug

Drug Farm’s DF-003 Earns FDA Rare Pediatric Disease Designation for ROSAH Syndrome

Fineline Cube Jan 17, 2024

Sino-US biotech company Drug Farm has announced that it has received Rare Pediatric Disease Designation...

Company Deals

SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China

Fineline Cube Jan 17, 2024

SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces...

Company Deals

Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution

Fineline Cube Jan 17, 2024

Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based...

Company Deals

XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China

Fineline Cube Jan 17, 2024

Sino-US AI drug development company XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...

Company Drug

InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248

Fineline Cube Jan 17, 2024

InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has...

Posts pagination

1 … 407 408 409 … 659

Recent updates

  • Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate
  • Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Company

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.